Tamtam Try Tamtam free
Asklepios logo

Asklepios account plan

Private healthcare provider in Germany

At a glance

Asklepios is a family-owned German hospital group with around 160 facilities, a 73,000-strong workforce and EUR 6,401.2 million revenue in FY2025.

Asklepios (Asklepios Kliniken GmbH & Co. KGaA, Hamburg) is a family-owned German hospital group founded in 1985, running around 160 healthcare facilities in 15 federal states: university and maximum-care hospitals, basic and standard care hospitals, rehabilitation clinics, medical care centres (MVZ), nursing services and online therapy. It holds majority stakes in RHÖN-KLINIKUM AG and MEDICLIN AG and took over the City of Hamburg hospitals in 2004. FY2025 revenue was EUR 6,401.2 million (+7.4%), EBITDA EUR 586.1 million and consolidated net income EUR 151.8 million, with 3,899,121 patients treated and 31,141 beds. The group has a 73,000-strong workforce (53,194 average FTEs in 2025). The Management Board is led by co-CEOs Joachim Gemmel and Marco Walker.

Business units

Strategic priorities

Answering the hospital reform
Asklepios responds to the KHVVG (in force 1 January 2025) and KHAG (from 2026) with specialisation, concentrated service ranges and regional clusters pooling expertise across sites and sectors.
Outpatientisation
Outpatient cases rose 8.1% to 3,098,698 in 2025 and 8.9% in H1 2026; the group follows patients from MVZ and outpatient care through inpatient stay and rehab.
Digitalisation and data
A Health Data Hub has managed clinical and administrative data centrally since November 2025, as the base for quality management, research, AI applications and data-driven care models; Virtual Wards and telemedical triage with nursing homes are running.
Nursing recruitment and retention
The Group-wide NEXT LEVEL NURSING initiative covers targeted recruiting, practice-based training, optimised procedures and integration of international staff, with recruiting at home and abroad.
Outcome-based quality
The CMO is introducing PROMs and PREMs and quality contracts that pay for whole treatment pathways, such as physiotherapy and app-based exercises around hip and knee replacements.
Economies of scale
Scale in procurement, IT, billing, controlling and administration, including a centralised procurement and logistics system and own warehouse sites.

Latest results

In H1 2026 (1 January to 30 June) revenue rose 4.8% to EUR 3,297.8 million and EBITDA 8.1% to EUR 323.4 million, lifting the margin to 9.8% from 9.5%; EAT was EUR 90.2 million. Patients rose 8.0% to 2,086,056, with outpatient cases up 8.9% and inpatient cases up 4.5%. Personnel costs rose 8.2% to EUR 2,318.2 million, 70.3% of revenue, on 54,650 FTEs; EUR 62.9 million of grant income for transformation costs helped results. Operating cash flow rose 30.7% to EUR 301.3 million and net debt/EBITDA was 2.4x. The 2026 forecast of roughly 2.0% organic growth and a slight improvement in key indicators was confirmed.

Investments and deals

Capex programme
Capex was EUR 602.5 million in 2025 (+25.8%, 9.4% of revenue), of which EUR 253.8 million subsidised, and EUR 180.1 million in H1 2026.
Central IT and data
Central IT investments were EUR 40.4 million in 2025, the largest single item, and Group-wide IT EUR 4.6 million in H1 2026.
Procurement and logistics
A centralised procurement and logistics system (EUR 11.6 million in 2025), own warehouse sites at Bad Oldesloe and Frankfurt, and a central warehouse in Bavaria (EUR 7.4 million in H1 2026).
Hospital sites
Main 2025 site investments were Klinik St. Georg (EUR 12.3 million), Universitätsklinikum Marburg (EUR 11.9 million), Klinik Nord (EUR 9.6 million) and Klinikum Frankfurt (Oder) (EUR 9.4 million).
Social promissory note
A first social Schuldschein of EUR 600.0 million was placed in October 2025 to refinance 2025, 2026 and 2027 maturities early.

Challenges and risks

Personnel costs and staff shortage
Employee benefits expense reached 70.3% of revenue in H1 2026 (68.1% a year earlier); personnel risk, including staff shortage, PpUGV staffing rules and wage agreements, is rated medium for 2026.
Hospital reform uncertainty
Management warns the reform's long-term impact is not yet certain and may bring additional adverse effects on earnings; it criticises structural rather than outcome-based quality measurement.
Billing and budget risk
Service, revenue, documentation and budget risks, including billing disputes, structural requirements and hybrid DRGs, are rated medium for 2026.
Construction and investment risk
Cost overruns, falling grant ratios and climate-related needs are rated medium; the overall risk position increased versus the previous year.

What leadership says

“financial success and sustainable growth are essential foundations for delivering the highest standard of medical care”

Hafid Rifi, CFO · Annual Report 2025, April 2026

“Modern data platforms, AI-based applications and digital networking create new opportunities to reduce the workload of our staff”

Management Board · Interim Report H1 2026 foreword, 27 August 2026

“many hospitals in Germany have responded with ad hoc, short-term solutions, leaving them in a state of near-perpetual crisis”

Management Board · Annual Report 2025, letter of the Management Board

“Wir haben noch nie so viel eingestellt”

PD Dr. Sara Sheikhzadeh, Chief Medical Officer · Level Up Klinikführung podcast, 17 November 2025 ("we have never hired so much")

Where a supplier can help

Staff workload reduction
Tied to the personnel cost challenge and the digitalisation priority: tools that cut documentation and administrative work for clinicians fit a group whose personnel costs reached 70.3% of revenue and whose board looks to AI to reduce staff workload.
Nursing recruiting and onboarding
Tied to the NEXT LEVEL NURSING initiative: recruiting, international staff integration and training offerings support a group that says it has never hired so much.
Data, AI and telemedicine
Tied to the Health Data Hub and Virtual Wards: suppliers of clinical data integration, remote monitoring and device-to-hospital-information-system connectivity have a live programme to plug into.
Revenue cycle and billing
Tied to the billing and budget risk: coding, documentation and billing-dispute tools address a risk rated medium for 2026 amid hybrid DRGs.
Centralised procurement and logistics
Tied to the procurement and logistics investments: framework-contract suppliers and logistics technology match the push for standardised product ranges across RHÖN-KLINIKUM and the wider group.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Asklepios?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Asklepios

What does Asklepios do?

Asklepios is a family-owned German healthcare group running around 160 facilities in 15 federal states, including acute hospitals, university hospitals, rehabilitation clinics, medical care centres and nursing services.

What is Asklepios's revenue?

FY2025 revenue was EUR 6,401.2 million (+7.4%), with EBITDA of EUR 586.1 million and net income of EUR 151.8 million. H1 2026 revenue was EUR 3,297.8 million.

How many employees does Asklepios have?

A 73,000-strong workforce, with 53,194 average FTEs in 2025 and 54,650 FTEs in H1 2026.

Who leads Asklepios?

The Management Board comprises co-CEOs Joachim Gemmel and Marco Walker, CFO Hafid Rifi and CMO PD Dr. Sara Sheikhzadeh. The group is family-owned and was founded on the vision of Dr. Bernard große Broermann.

What is Asklepios's strategy?

Specialisation and regional clusters in response to the German hospital reform, a shift to outpatient care, digitalisation through its Health Data Hub, and nursing recruitment through NEXT LEVEL NURSING.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)